Alternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma progression

Area of Science:

• Neuro-oncology
• Molecular biology
• Cancer research

Background:

• Alternative splicing of Intersectin1 (ITSN1) generates ITSN1-S and ITSN1-L isoforms.
• The distinct roles of ITSN1 isoforms in cancer, particularly glioma, are largely unknown.
• Previous studies indicated ITSN1-S promotes glioma development.

Purpose of the Study:

• To investigate the function of ITSN1-L in glioma progression.
• To elucidate the molecular mechanisms by which ITSN1-L inhibits glioma.
• To explore the therapeutic potential of targeting ITSN1 isoforms in glioma.

Main Methods:

• Transcriptome analysis of a large glioma cohort.
• In vivo and in vitro experiments to assess ITSN1-L function.
• Co-immunoprecipitation and Western blotting to study protein interactions and pathways.

Main Results:

• ITSN1-L exhibits an inhibitory role in glioma progression, contrasting with ITSN1-S.
• ITSN1-L decreases cell motility via interaction with α-tubulin and HDAC6-mediated deacetylation.
• ITSN1-L attenuates cell-substrate adhesion through the FAK/integrin β3 pathway.
• ITSN1-L enhances cell-cell adhesion by upregulating N-cadherin expression and membrane localization.

Conclusions:

• ITSN1 isoforms, ITSN1-S and ITSN1-L, exert opposing functions in glioma development.
• Targeting ITSN1 alternative splicing, by upregulating ITSN1-L and downregulating ITSN1-S, may represent a novel glioma treatment strategy.
• This study highlights the critical role of alternative splicing in glioma progression and suggests splicing-level control as a therapeutic avenue.